Thoracic SMARCA4-deficient undifferentiated tumor

Area of Science:

• Oncology
• Molecular Biology
• Genetics

Background:

• Thoracic SMARCA4-deficient undifferentiated tumor (SMARCA4-UT) is a recently identified smoking-related malignancy.
• Its development stems from the loss of SMARCA4 and SMARCA2 subunits of the mammalian switch/sucrose nonfermenting (SWI/SNF) ATPase-dependent chromatin remodeling complex.
• This complex is crucial for regulating gene expression, impacting cellular processes like development, proliferation, and apoptosis.

Purpose of the Study:

• To review the clinical characteristics, diagnosis, treatment, and prognosis of SMARCA4-UT.
• To consolidate current knowledge on this rare thoracic malignancy.
• To highlight emerging therapeutic strategies.

Main Methods:

• Literature review of clinical studies and case reports on SMARCA4-UT.
• Analysis of genomic and morphological data comparing SMARCA4-UT with similar tumors.
• Synthesis of information on treatment outcomes, including chemotherapy and targeted therapies.

Main Results:

• SMARCA4-UT primarily affects the mediastinum and lung parenchyma, presenting as a large infiltrative mass.
• While morphologically similar to malignant rhabdoid tumor (MRT) and small cell carcinoma of the ovary of the hypercalcemic type (SCCOHT), it has distinct genomic features.
• Chemotherapy is a standard treatment, but its effectiveness is uncertain; however, enhancer of zeste homolog 2 (EZH2) inhibitors have shown promise in some cases.

Conclusions:

• SMARCA4-UT is a distinct entity characterized by SWI/SNF complex deficiency.
• Accurate diagnosis requires integrating clinical, morphological, and genomic data.
• Further research into targeted therapies, such as EZH2 inhibitors, is warranted for improved patient outcomes.